Mauna Kea Technologies to experience strong growth in Q1 2026

Mauna Kea Technologies announced revenues of €1,527,000 for the first quarter of 2026, representing a 68% increase at constant exchange rates compared to the previous year. In the United States, sales grew by 34% at constant exchange rates, primarily driven by the adoption of technologies for the treatment of pancreatic cysts. Internationally, a 326% increase was observed, fueled by demand for CellTolerance®.

According to CEO Sacha Loiseau, this growth stems from increased clinical adoption and strategic investments, particularly in Southern California with the opening of a center dedicated to food intolerances. New fee-for-service contracts are also expected to bolster financial results in the coming months.